Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Cash at Beginning of Period?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Cash at Beginning of Period is 
$10.0B (1Y +12.5% )

ALXN Stock Price & Cash at Beginning of Period

Cash at Beginning of Period for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Cash at Beginning of Period

chevron_right 2021 $2.3B +455x
( +25.5% / year avg)
chevron_left 1995 $5.1M
vertical_align_top Peak $10.2B +1990x
vertical_align_bottom Bottom $5.1M
arrow_drop_up # Up Years 18 18 of 27
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.1x the rate relative to it's cash at beginning of period over the same period.
  • If ALXN grows it's stock at the same rate as it's cash at beginning of period (+25.5%/year) , it's stock price will grow +969% and hit $1053.77 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 18 years (0%) it's cash at beginning of period were also up.
  • ALXN Historical Cash at Beginning of Period Table
    in $ million
    Year Cash at Beginning of Period YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $2,328 -77.1% - -
    4/1/2020 $10,155 65.7% - -
    4/1/2019 $6,129 157.2% - -
    4/1/2018 $2,382 -20.1% - -
    4/1/2017 $2,982 3.4% - -
    4/1/2016 $2,883 -26.7% - -
    4/1/2015 $3,935 52.5% - -
    4/1/2014 $2,580 -33.0% - -
    4/1/2013 $3,854 79.7% - -
    4/1/2012 $2,144 92.4% - -
    4/1/2011 $1,114 54.6% - -
    4/1/2010 $720 31.7% - -
    4/1/2009 $547 37.5% - -
    4/1/2008 $397 -12.9% - -
    4/1/2007 $456 166.7% - -
    4/1/2006 $171 -44.2% - -
    4/1/2005 $306 46.5% - -
    4/1/2004 $209 32.0% - -
    4/1/2003 $158 -65.4% - -
    4/1/2002 $457 -32.2% - -
    4/1/2001 $675 106.3% - -
    4/1/2000 $327 216.5% - -
    4/1/1999 $103 -17.7% - -
    4/1/1998 $125 215.0% - -
    4/1/1997 $39 39.5% - -
    4/1/1996 $28 460.8% - -
    4/1/1995 $5 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The total amount of cash a company has at the beginning of its reporting period.

    For more detailed definitions, please see Investopedia.